Literature DB >> 10666194

Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study.

M Stanulla1, M Schrappe, A M Brechlin, M Zimmermann, K Welte.   

Abstract

Glutathione S-transferases (GSTs) have been associated with outcome in human cancers treated with cytotoxic chemotherapy. In a case-control study, we investigated the association between polymorphisms within the GSTM1, GSTT1, and GSTP1 genes and risk of relapse in childhood acute lymphoblastic leukemia (ALL). Cases were relapsed patients. Controls were successfully treated patients with a minimum follow-up of 5 years. The null genotype (absence of both alleles) for GSTM1 or GSTT1 conferred a 2-fold (OR = 0.5, 95% CI = 0. 23-1.07, P =.078) and 2.8-fold (OR = 0.36, 95% CI = 0.13-0.99, P =. 048) reduction in risk of relapse, respectively, relative to the presence of the GSTM1 or GSTT1 gene. The GSTP1 Val(105)/Val(105) genotype showed a 3-fold decrease in risk of relapse (OR = 0.33, 95% CI = 0.09-1.23, P =.099) in comparison to the combined category of Ile(105)/Val(105) and Ile(105)/Ile(105 )genotypes. No particular associations with relapse were observed for the GSTP1 polymorphism at codon 114. The risk of relapse when having 1 of the low-risk genotypes (GSTM1 null, GSTT1 null, GSTP1 Val(105)/Val(105)) decreased 1.9-fold (OR = 0.53, 95% CI = 0.24-1.19, P =.123), and the risk when having 2 or 3 low-risk genotypes 3.5-fold (OR = 0.29, 95% CI = 0.06-1.37, P =.118), compared with individuals having no low-risk genotype (P for trend =.005). Our results suggest that polymorphisms within genes of the GST superfamily may be associated with risk of relapse in childhood ALL. (Blood. 2000;95:1222-1228)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666194

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  A comparison of glutathione S-transferase mutant frequencies in healthy Han and Uygur Chinese.

Authors:  Shi-Long Zhong; Shufeng Zhou; Min Huang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

2.  Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome.

Authors:  Chiara Oretti; Sara Marino; Fabio Mosca; Maria Rosa Colnaghi; Sara De Iudicibus; Ilenia Drigo; Gabriele Stocco; Fiora Bartoli; Giuliana Decorti; Sergio Demarini
Journal:  Eur J Clin Pharmacol       Date:  2009-01-29       Impact factor: 2.953

3.  The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1.

Authors:  Udo Vester; Birgitta Kranz; Stephanie Zimmermann; Rainer Büscher; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2005-02-17       Impact factor: 3.714

4.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

Authors:  Jose Claudio C Rocha; Cheng Cheng; Wei Liu; Shinji Kishi; Soma Das; Edwin H Cook; John T Sandlund; Jeffrey Rubnitz; Raul Ribeiro; Dario Campana; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

5.  Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.

Authors:  Lindsay Kilburn; M Fatih Okcu; Tao Wang; Yumei Cao; Amy Renfro-Spelman; Kenneth D Aldape; Mark R Gilbert; Melissa Bondy
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

6.  Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.

Authors:  Xuesong Han; Tongzhang Zheng; Francine M Foss; Qing Lan; Theodore R Holford; Nathaniel Rothman; Shuangge Ma; Yawei Zhang
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

7.  Germline genetic variation and treatment response on CCG-1891.

Authors:  Dana M Sepe; Thomas McWilliams; Jinbo Chen; Aaron Kershenbaum; Huaqing Zhao; Mei La; Meenakshi Devidas; Beverly Lange; Timothy R Rebbeck; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2011-05-25       Impact factor: 3.167

8.  Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

Authors:  Nadia Barahmani; Sarah Carpentieri; Xio-Nan Li; Tao Wang; Yumei Cao; Laura Howe; Lindsay Kilburn; Murali Chintagumpala; Ching Lau; M Fatih Okcu
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

9.  Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.

Authors:  In-Wha Kim; Hwi-yeol Yun; Boyoon Choi; Nayoung Han; Myeong Gyu Kim; Seonyang Park; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

Review 10.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Authors:  Navin Pinto; Susan M Ludeman; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.